Biotest AG: Biotest expands plasma recovery capacities
Biotest AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest expands plasma recovery capacities
- New plasmapheresis centre in Nordhausen
- Number of stations operated by Biotest rises to 19 worldwide
- High degree of self-sufficiency makes Biotest more independent of
global market
Dreieich, 10. December 2008. Biotest AG has expanded its own capacities for
obtaining raw material for its fast-growing plasma protein business. The
company opened a plasmapheresis centre in Nordhausen, central Germany.
After a 12-month start-up phase, the station will supply around 25,000
litres of human blood plasma per year, which forms the basis of the
preparations used in immunological and coagulation treatments.
During the plasmapheresis process, plasma is separated from the blood,
while the remaining components are returned immediately to the donor. The
centre in Nordhausen is the ninth of its kind operated by Biotest in
Europe, and preparations are currently underway to open another station. In
addition, Biotest owns ten plasmapheresis centres in the USA.
'The opening of the centre brings us a step closer to our aim of being able
to obtain half of the plasma processed by us each year from our own
centres,' commented Chairman of the Management Board of Biotest AG,
Professor Gregor Schulz. The company intends to use this high level of
self-sufficiency to ensure that adequate raw materials are available for
production at all times. Furthermore, it is increasing its independence
from price movements in the global market.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,850
employees worldwide and its shares are listed in the Stock Exchange's SDAX.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth,
Tel: +49 (0) 6103 801-520,
e-mail: michael_ramroth@biotest.de
Fax: +49 (0) 6103 801-347
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
10.12.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
